(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2015- Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2015. OPERATING HIGHLIGHTS Opsumit® - Sales of CHF 208 million, increased patient recruitment momentum Opsumit - Launched in Japan and Spain in June 2015 Selexipag (Uptravi®) - FDA, EMA regulatory procedures on track Specialty franchise - Immunology portfolio advances Creation of vaccine start-up Vaxxilon - Innovating together with Max Planck Society FINANCIAL HIGHLIGHTS Product sales of CHF 1,008 million - Strong growth driven by Opsumit uptake Core earnings of CHF 423 million - Driven by commercial performance 2015 financial guidance upgrade:...
↧